Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197316 | 1.00 | TSHR (0.37) | TSHRALOX5GSTO1LTA4HPARP1 | |
| SCHEMBL1448846 | 0.77 | ESR1 (0.42) | ALOX5ALDH1A1 | |
| SCHEMBL2429212 | 0.77 | ESR1 (0.42) | ALOX5ALDH1A1 | |
| SCHEMBL2197076 | 0.75 | ALOX5 (0.51) | ALOX5ALDH1A1 | |
| SCHEMBL2576026 | 0.75 | ALOX5 (0.51) | ALOX5ALDH1A1 | |
| SCHEMBL1270470 | 0.75 | ALOX5 (0.51) | ALOX5ALDH1A1 | |
| SCHEMBL2198695 | 0.74 | MAPT (0.39) | ALOX5ALDH1A1 | |
| SCHEMBL3558684 | 0.74 | NAMPT (0.43) | — | |
| SCHEMBL2107176 | 0.73 | PPARA (0.41) | TSHRALOX5ALDH1A1 | |
| SCHEMBL2239284 | 0.73 | PPARA (0.41) | TSHRALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | TSHR 3070/4885ALOX5 4003/4885GSTO1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.